Metabolic State Medicine.

For over a century, pharmaceutical development has followed what might be called Target-First Medicine: identify a molecular target, design a drug that binds to it, and assume that target engagement translates into clinical benefit. This approach has delivered remarkable successes. But the assumption at its core — that hitting the target is sufficient — has a problem.

Across neurodegeneration, cancer, epilepsy, heart failure, and metabolic disease, converging evidence shows that many of the most devastating conditions share a common upstream cause — not a broken molecule, but a broken state: the failure of cellular energy systems to meet the demands of healthy function.

Metabolic State Medicine represents a paradigm shift. Rather than targeting individual molecules, we focus on restoring defined metabolic states — the physiological conditions that enable cells and tissues to function normally.

The evidence for this is not theoretical. SGLT2 inhibitors produce 25–26% cardiovascular mortality reduction in non-diabetic patients through metabolic state shift, not glucose reduction (McMurray et al., NEJM 2019). Anti-amyloid drugs clear amyloid equally across patient groups but produce vastly different clinical outcomes depending on brain metabolic status (Evans et al., 2023). The ketogenic diet outperforms 9 of 11 approved anti-seizure drugs in the hardest-to-treat epilepsy patients (Cochrane 2020). These aren't edge cases. They're pattern-level signals across the most important disease areas in medicine.